Rectovaginal Fistula Market Share

Rectovaginal Fistula Market Overview

The Rectovaginal fistula market size is anticipated to reach USD 623 Million by 2032 at 6.28% CAGR during the forecast period 2023-2032, says Market Research Future. Rectovaginal fistula is abnormal connection between lower portion of large intestine- rectum-vagina. There are various causes of rectovaginal fistula such as Crohn's disease, cancer or radiation treatment in pelvic area, surgery involving vagina, perineum, rectum or anus, injuries during childbirth, and others.

The factors such as increasing prevalence pelvic cancer, Crohn’s disease is the major driving factors for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer treatment. Furthermore, growing diagnosis methods for rectovaginal fistula will boost the market growth during forecast period.

However, high cost of the surgery may hamper the growth of the market during the forecast period.

According to National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.

Segmentation

The rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.

By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.

Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.

The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.

The rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.  

The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.   

The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.    

Key players

Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A are some of the prominent players in the rectovaginal fistula market.

Regional Market Summary

Global Rectovaginal Fistula Share (%), by Region

Source: White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the rectovaginal fistula market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.

Europe is expected to hold the second largest position in the Dural Arteriovenous Fistulas Treatment market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU). 

The rectovaginal fistula market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biotechnology and pharmaceutical sector and growing number of target population in the region.   

The Middle East & Africa has the lowest share of the rectovaginal fistula market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector. 

Market of Rectovaginal Fistula, by Diagnosis:

• Physical Exam


• Contrast Tests


• Blue Dye Test


• Computerized Tomography (CT) Scan


• Magnetic Resonance Imaging (MRI)


• Anorectal Ultrasound


• Anorectal Manometry


• Others

Market of Rectovaginal Fistula, by Treatment:

• Medications




• Antibiotics


• Infliximab




• Surgery




• Sewing an Anal Fistula Plug or Patch of Biologic Tissue into the Fistula


• Using a Tissue Graft


• Repairing the Anal Sphincter Muscles


• Performing a Colostomy before Repairing a Fistula in Complex or Recurrent Cases

Market of Rectovaginal Fistula, by End User:

• Hospitals & Clinics


• Diagnostic Centers


• Academic Institutions and Research Organizations


• Others

Market of Rectovaginal Fistula, by Region:

• Americas




• North America




• US


• Canada




• Latin America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa

Market of Rectovaginal Fistula, by Key Players:

• Cook Medical


• Takeda Pharmaceutical Company


• Johnson & Johnson Services Inc.


• Pfizer Inc.


• Allergan


• AbbVie Inc


• Novartis International AG


• Bayer AG


• Bristol-Myers Squibb


• Boehringer Ingelheim GmbH


• Hoffmann-La Roche


• Eli Lilly and Company


• GlaxoSmithKline plc


• Sanofi S.A


• Others

Intended Audience:

• Pharmaceutical and Biotechnological Companies


• Contract Research Organizations


• Academic and Research Institutes


• Government Associations